search
Back to results

Functional Near-infrared Spectroscopy in Unconscious Patients (fNIRS)

Primary Purpose

Nervous System Diseases, Healthy Subjects

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
single-center prospective pilot study
Sponsored by
Emanuela Keller
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Nervous System Diseases focused on measuring severe cerebral hemorrhage, ischemic stroke, unconscious neurocritical care patients, functional near-infrared spectroscopy, evoked potentials, electroencephalography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria - experimental group:

  • Patients of either sex with severe hemorrhagic, ischemic stroke or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation treated at the Institute of Intensive Care Medicine, University Hospital Zurich
  • Unconsciousness (GCS < 9) or sedated to the severity of the disease (•o For the subgroup of patients included in the fNIRS-EEG measurement unconscious patients are defined as not responding to verbal stimuli. The motor response to pain should be one of the following: no response to pain / extensor response / flexor response / localize to pain)
  • Age ≥ 18 years
  • Signed informed consent obtained from legal representative
  • Measurement logistically and technical possible within the first 7 days after admission

Inclusion Criteria - control group:

  • Subjects of either sex
  • Conscious (GCS = 15)
  • Age ≥ 18 years
  • Signed informed consent

Exclusion Criteria - experimental group:

  • Patients age < 18 years
  • Positive pregnancy test for any female of childbearing potential or breast feeding female
  • Previous auditory complaints or any ear diseases
  • No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.)
  • Any history of previous cerebral or brainstem disease
  • Concomitant instable critical illness (e.g. sepsis, multi-organ failure, hemodynamic or respiratory instability)
  • Acute status epilepticus
  • Clinical recovery (GCS ≥ 9) or death before enrolment of the study

Exclusion Criteria - control group:

  • Subjects age < 18 years
  • Positive pregnancy test for any female of childbearing potential or breast feeding female
  • Previous auditory complaints or any ear diseases
  • No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.)
  • Any history of previous cerebral or brainstem disease

Sites / Locations

  • University Hospital ZurichRecruiting
  • University Hospital ZurichRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Experimental (unconscious)

Control group (healthy, conscious)

Arm Description

fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)

fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)

Outcomes

Primary Outcome Measures

Results of fNIRS examination to those of evoked potentials (presence or absence of response) in unconscious ICU patients with severe hemorrhagic, ischemic strokes or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation.
Correlation of presence of typical relative changes in NIRS pattern (increase of oxygenated hemoglobin and decrease of deoxygenated haemoglobin) to positive response to somatosensory and auditory stimulation measured by electroencephalography (change of cortical electrical acivity after stimulation). Both signals will be either present or absent.

Secondary Outcome Measures

Evaluation of the agreement of the results of the experimental group and the control group
Frequency of presence of typical relative changes in NIRS pattern (increase of oxygenated hemoglobin and decrease of deoxygenated haemoglobin) compared in healthy controls and patients.

Full Information

First Posted
November 12, 2020
Last Updated
November 3, 2022
Sponsor
Emanuela Keller
search

1. Study Identification

Unique Protocol Identification Number
NCT04746820
Brief Title
Functional Near-infrared Spectroscopy in Unconscious Patients
Acronym
fNIRS
Official Title
Prognostic Value of Functional Near-infrared Spectroscopy in Unconscious Neurocritical Care Patients- a Prospective Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 15, 2020 (Actual)
Primary Completion Date
December 31, 2026 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Emanuela Keller

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study design is a single-center prospective pilot study. Hypothesis: Results of cerebral fNIRS examination in unconscious patients with severe hemorrhagic or ischemic stroke in the ICU are congruent with the results of SSEP and AEP. Hence, making it a potential prognostic tool for unconscious ICU patients. In a specific subgroup of unconscious patients after cardiac arrest and cardiopulmonary resuscitation the fNIRS measurement is congruent with the results of electroencephalography (EEG). The primary purpose of this study is to evaluate the agreement of the results of fNIRS examination to those of evoked potentials and EEG in unconscious ICU patients with severe hemorrhagic, or ischemic strokes or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation. fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects. To compare fNIRS with evoked potentials there are two test phases: The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP The cerebral response to an auditory stimulus is measured by fNIRS and AEP To avoid biases the following has to be considered: The timing of the measurements plays an important role. A time difference between compared measurements can influence the outcome significantly due to deterioration or recovery of the neuronal network during the time gap. Therefore, fNIRS and evoked potentials will be measured simultaneously. If the compared measurement methods are conducted by the same researcher the possibility of bias is high. Hence, two different researcher will conduct each one measurement without knowing the results of each other during the measurement.
Detailed Description
Severe ischemic and hemorrhagic stroke, as well cardiac arrest even after successful cardiopulmonary reanimation are great causes of morbidity and mortality in Europe and worldwide. Although prevention and therapy strategies, have been successfully improved during the past decades, the global stroke burden - measured in disability adjusted life years (DALY) - is still great. Specifically, the improvements of intensive care treatments and neurosurgical procedures have lowered mortality rates, but simultaneously have increased survivors with severe disorder of consciousness (DoC) or persistent disabilities. As a result, an early prognosis in unconscious patients suffering from severe stroke in the intensive care unit (ICU) becomes more important for the clinician. An early reliable prognosis enables the clinician to empower the surrogates of an unconscious patient to make choices consistent with his preferences. It improves also overall patient management in the NICU and helps to identify an appropriate rehabilitation care. Since clinical assessment of comatose Patients is limited, other examinations are needed to enhance the reliability of a prognosis. Evoked potentials, especially somatosensory and auditory evoked potentials (SSEP and AEP) are well established prognostic tools in unconscious ICU patients. The advantage of evoked potentials over clinical assessments such as the Glasgow coma score (GCS) or laboratory values are that they are not influenced by intensive care interventions, and have a higher interrater reliability. They are also resistant to metabolic changes or sedation. Electroencephalography (EEG) is another established prognostic tool in comatose patients. However, both, evoked potential and EEG are highly vulnerable to artefacts and expensive due to high workforce requirements. Functional near-infrared spectroscopy (fNIRS) is a promising strictly non-invasive, bedside examination. It is based on the finding that infrared light is absorbed by oxygenated and deoxygenated haemoglobin. Brain activation can be measured with fNIRS due to an increase of oxygenated haemoglobin and decrease of deoxygenated haemoglobin. Different studies show that brain activation as a response to peripheral somatosensory and auditory stimulation as it is conducted in SSEP and AEP can be detected by fNIRS. Recent studies investigated also the use of fNIRS in unconscious patients. However, it is unknown whether and how the brain activation measured by fNIRS due to sensory stimulation correlates to the measurements of evoked potentials in unconscious patients and if it has any prognostic value in unconscious patients. Therefore, the investigator aims to compare fNIRS with SSEP and AEP in unconscious neuro-intensive care patients suffering from severe hemorrhagic or ischemic stroke and in a control group with healthy conscious subjects. Hence, making it a potential prognostic tool for unconscious ICU patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nervous System Diseases, Healthy Subjects
Keywords
severe cerebral hemorrhage, ischemic stroke, unconscious neurocritical care patients, functional near-infrared spectroscopy, evoked potentials, electroencephalography

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects. Experimental group: All included patients will be examined with fNIRS, sSEP and AEP examination within 7 days after admission. fNIRS, SSEP and AEP examination. Control group: The control group will be recruited among employees of the University Hospital Zurich, which are not subordinate to the PI and will have the same examinations as the experimental group.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental (unconscious)
Arm Type
Experimental
Arm Description
fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
Arm Title
Control group (healthy, conscious)
Arm Type
Sham Comparator
Arm Description
fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
Intervention Type
Other
Intervention Name(s)
single-center prospective pilot study
Intervention Description
fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects. To compare fNIRS with evoked potentials there are two test phases: The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP The cerebral response to an auditory stimulus is measured by fNIRS and AEP
Primary Outcome Measure Information:
Title
Results of fNIRS examination to those of evoked potentials (presence or absence of response) in unconscious ICU patients with severe hemorrhagic, ischemic strokes or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation.
Description
Correlation of presence of typical relative changes in NIRS pattern (increase of oxygenated hemoglobin and decrease of deoxygenated haemoglobin) to positive response to somatosensory and auditory stimulation measured by electroencephalography (change of cortical electrical acivity after stimulation). Both signals will be either present or absent.
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Evaluation of the agreement of the results of the experimental group and the control group
Description
Frequency of presence of typical relative changes in NIRS pattern (increase of oxygenated hemoglobin and decrease of deoxygenated haemoglobin) compared in healthy controls and patients.
Time Frame
1 day
Other Pre-specified Outcome Measures:
Title
Safety endpoints (adverse events)
Description
Incidence of adverse events (for evoked potentials: skin infection or bleeding at the puncture site of electrode needles; for fNIRS: local allergic reaction against plaster or burning of the skin)
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria - experimental group: Patients of either sex with severe hemorrhagic, ischemic stroke or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation treated at the Institute of Intensive Care Medicine, University Hospital Zurich Unconsciousness (GCS < 9) or sedated to the severity of the disease (•o For the subgroup of patients included in the fNIRS-EEG measurement unconscious patients are defined as not responding to verbal stimuli. The motor response to pain should be one of the following: no response to pain / extensor response / flexor response / localize to pain) Age ≥ 18 years Signed informed consent obtained from legal representative Measurement logistically and technical possible within the first 7 days after admission Inclusion Criteria - control group: Subjects of either sex Conscious (GCS = 15) Age ≥ 18 years Signed informed consent Exclusion Criteria - experimental group: Patients age < 18 years Positive pregnancy test for any female of childbearing potential or breast feeding female Previous auditory complaints or any ear diseases No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.) Any history of previous cerebral or brainstem disease Concomitant instable critical illness (e.g. sepsis, multi-organ failure, hemodynamic or respiratory instability) Acute status epilepticus Clinical recovery (GCS ≥ 9) or death before enrolment of the study Exclusion Criteria - control group: Subjects age < 18 years Positive pregnancy test for any female of childbearing potential or breast feeding female Previous auditory complaints or any ear diseases No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.) Any history of previous cerebral or brainstem disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Emanuela Keller, Prof. Dr.
Phone
+41 44 255 56 71
Email
emanuela.keller@usz.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emanuela Keller, Prof. Dr.
Organizational Affiliation
University Hospital, Zürich
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Zurich
City
Zurich
ZIP/Postal Code
CH-8091
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emanuela Keller, Prof MD
Phone
+41 44 255 56 71
Email
Emanuela.Keller@usz.ch
First Name & Middle Initial & Last Name & Degree
Giselle Golby
Phone
+41442559891
Email
giselle.golby@usz.ch
Facility Name
University Hospital Zurich
City
Zurich
ZIP/Postal Code
CH-8091
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emanuela Keller, Prof MD
Phone
+41 44 255 56 71
Email
Emanuela.Keller@usz.ch

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Functional Near-infrared Spectroscopy in Unconscious Patients

We'll reach out to this number within 24 hrs